Palonosetron in Moderately and Highly Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04935)(COMPLETED)
Status:
Completed
Trial end date:
2008-02-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of single IV doses of
Onicit® (Palonosetron) 0.25 mg in the prevention of acute and delayed nausea and vomiting
associated with moderate and highly emetogenic chemotherapy.